Who We Are

By supporting the brain’s ability to repair itself while keeping a sharp focus on unique, noninvasive platform technologies, we are dedicated to developing and expanding treatment options to increase patients’ independence and overall quality of life.

Our Mission

Our mission is to help individuals affected by functional neurological deficits get back on their feet and regain their independence with our portable neuromodulation technology.

Our Vision

Our vision for the future is to provide the go-to portable therapy that promotes neuromodulation and induces neuroplasticity for anyone affected by dysfunctional neurological conditions and become the new standard of care.

The History of Helius


( How We Got Here )

2018

PoNS Therapy™ receives authorization in Canada for the treatment of balance deficit due to mmTBI

2019

PoNS™ becomes available commercially, for the first time, to patients in Canada for the treatment of balance deficit due to mmTBI

2020

Helius Medical receives FDA Breakthrough Designation for PoNS treatment of gait deficit due to symptoms of MS

Helius Medical submitted request for FDA de novo classification

2020

PoNS Therapy receives authorization in Canada for the treatment of gait deficit due to mild and moderate symptoms of MS

2021

Helius Medical receives US marketing authorization for the PoNS® device

2021

Helius Medical receives FDA breakthrough designation for PoNS treatment of gait deficit due to stroke

2021

Helius Medical receives PoNS® market authorization in Australia

2022

PoNS® becomes available commercially by prescription, for the first time, to patients in the U.S. for the treatment of gait deficit due to MS

2022

Helius Medical launches online PoNS Therapy training for rehabilitation specialists

Our Leadership

Get to know the hearts and minds of the driven individuals that lead Helius Medical. With countless years of combined experience, our team of leaders not only steers the company in the right direction, but toward the goal of changing the standard of care in neuromodulation technology.